All News

Part A results from the 2-part LILAC study show that the therapy significantly reduced disease activity based on active joint count in individuals compared with the placebo.

Researchers have identified hydroquinine as a potential treatment against drug-resistant bacteria, which can cause infections with a 70% mortality rate.

Study suggests gene therapy may effectively treat young children who were born colorblind via pathways connecting the brain and the retina.

Many health care systems use these products to provide similar but cheaper clinical outcomes.

Research suggests that subcutaneous insulin aspart is a cost-effective and accessible treatment option that could allow children with type 1 diabetes to avoid the ICU after a mild episode of diabetic ketoacidosis.

The long-acting, once-daily hormone controls high blood sugar in individuals aged 1 year or older with diabetes.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

Research indicates that poor technique or failure to follow up-to-date standards and protocols could lead to injury or even death of patients who need compounded medications.

Key responsibilities include providing recommendations, administering vaccinations, disseminating evidence-based advice, reducing spread of influenza in communities.

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

Investigators find 8 of 10 of the most common symptoms were reported between 50% and 80% less often among those who received at least 2 Pfizer-BioNTech vaccinations.

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.

It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.

Research suggests that non-traditional complications from type 2 diabetes are hospitalizing more people now than they did 20 years ago.

Results demonstrated a 64.5% confirmed objective response rate in patients treated with the investigational combination.

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

Prescribers signed a letter expressing concerns about recommendations for restrictions on compounded hormones, which millions of women and other patient populations rely on.

This week, Joanna speaks with Lydia Fenet, ambassador at Christie’s Auction House and best-selling author of The Most Powerful Woman in the Room is You, to discuss the professional side of wellness.

Case report describes severe complications from spontaneous bladder rupture caused by herpes zoster-associated urinary retention.

Asceniv is a plasma-derived polyclonal IVIG drug product designed to prevent serious bacterial infections in patients with primary humoral immunodeficiency disease.

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.

Pharmacy Times spoke with Carina Dolan, PharmD, Editor in Chief of the Pharmacy Market Outlook, about the highlights and the big picture moving forward for hospitals and health systems.

Although OTC medications are generally considered safe when used as directed, there are some key drug interactions for pharmacists to keep in mind when helping patients choose an OTC product.

Hawaii has a distinct culture, and the students said that has led them to have unique perspectives on culturally competent care.

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Modification is based on phase 3 FIGARO-DKD clinical trial investigating CV and kidney outcomes in more than 13,000 patients with CKD associated with type 2 diabetes.